Everest Medicines
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
450 Lexington Ave Ste 39B, New York, New...Phone Number
+86 1065837510Website
www.everestmedicines.comRevenue
$8.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eleven potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company's therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases.Explore more
Everest Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Everest Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Everest Medicines is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Everest Medicines
Website visits: Recent activity has been detected on your website
Check if Everest Medicines has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Everest Medicines recently announced quarterly report
Product Launch: Get notified when Everest Medicines launches new products
Funding: Get notified immidiatlly once Everest Medicines has new funding data
Click to see if Everest Medicines had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Everest Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Everest Medicines
Compare insights from companies similar to Everest Medicines, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Everest Medicines is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Everest Medicines is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Everest Medicines.
Everest Medicines financials insights
Gather financial insights about Everest Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$50M
2020
Series C
$310M
Everest Medicines Tech Stack
A closer look at the technologies used by Everest Medicines
Most Recent Scoops
Open Position
Open Position
Partnership
Project
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Partnership
Everest Medicines has entered into an exclusive licensing and collaboration agreement with Everest Medicine to develop and commercialize CBOR Brutinib (EBER001), a reversible BTK inhibitor. Under the agreement, Everest Medicines will receive development and commercialization rights to CBOR Brutinib in global markets outside of China and certain countries in East and Southeast Asia.
Project
Everest Medicines News & Media
Everest Medicines Announces Participation in Upcoming Investor Conferences
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and...Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-cEverest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China
HONG KONG, Jun 26, 2026 - (ACN Newswire) - June 26, 2026, Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The on-schedule acceptEverest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL® (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use as an adjunct to diet and exercise to reduce
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Everest Medicines
Sign Up For FreeTo access detailed company insights
Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs,... Read More
